Catalyst Event
Biogen Inc (BIIB) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
3/19/2026, 12:00:00 AM
Announced that the U.S. FDA granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus (CLE) and will present new Phase 2 data on March 28, 2026. This designation is expected to have a low price impact of at least 1%, scheduled.
Korean Translation
미국 FDA가 피부 홍반성 루푸스(CLE) 치료제 리티필리맙(litifilimab)에 대해 혁신 치료제 지정을 부여했으며, 2026년 3월 28일에 새로운 2상 임상 데이터를 발표할 것이라고 밝힘. 이 지정은 최소 1%의 낮은 주가 영향을 미칠 것으로 예상됨.
Related Recent Events
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release is scheduled for June 12, 2026, which is expected to have a high market impact (>=10%) as it provides the next official update on financial performance scheduled.
6/12/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Q4 and full-year fiscal 2026 earnings release scheduled.
5/20/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The next quarterly earnings release on 2026-05-14 is scheduled.
5/14/2026, 12:00:00 AM
Roblox Corp (RBLX) · Earnings Release
Roblox's Q1 2026 earnings report is scheduled. Earnings releases typically cause significant price movement, but the immediate impact of the scheduling itself is estimated to be Low.
5/7/2026, 12:00:00 AM
Rockwell Automation Inc. (ROK) · Earnings Release
Medium importance is assigned as earnings releases typically result in significant price volatility; Q2 2026 earnings release is scheduled; analysts forecast EPS of approximately $2.88 estimated.
5/5/2026, 12:00:00 AM